| Current Price | $24.48 | Mkt Cap | $1.0B |
|---|---|---|---|
| Open | $24.06 | P/E Ratio | -12.00 |
| Prev. Close | $24.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $23.53 - $25.17 | Volume | 717,174 |
| 52-Wk Range | $13.84 - $51.59 | Avg. Daily Vol. | 710,341 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
| Current Price | $24.48 | Mkt Cap | $1.0B |
|---|---|---|---|
| Open | $24.06 | P/E Ratio | -12.00 |
| Prev. Close | $24.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $23.53 - $25.17 | Volume | 717,174 |
| 52-Wk Range | $13.84 - $51.59 | Avg. Daily Vol. | 710,341 |
The best Bull and Bear pitches based on recency and number of recommendations.
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.
Read the most recent pitches from players about SAVA.
Recs
wpshil78
(33.21)
Submitted: 11/8/2022 3:44:00 PM :
Start Price:
$34.83
NASDAQ:SAVA Score:
+41.64
It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.
Recs
TMFjimhalley
(< 20)
Submitted: 7/12/2021 6:46:55 PM :
Start Price:
$100.15
NASDAQ:SAVA Score:
-73.93
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
Recs
kfox
(< 20)
Submitted: 2/2/2021 4:28:30 PM :
Start Price:
$33.39
NASDAQ:SAVA Score:
-38.89
They just released information of a trial they did with their treatment for Alzheimer's Disease. The results of the trial were positive, patients had an improvement in cognition and behavior. the name of the treatment/drug is Simufilam.
Find the members with the highest scoring picks in SAVA.
medeaschild (58.23) Score: +3,036.23
The Score Leader is the player with the highest score across all their picks in SAVA.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| medeaschild | 58.23 | 12/26/2018 |
|
NS | $0.76 | +3,118.09% | +81.86% | +3,036.23 | 0 Comment | |
| marcet | 74.83 | 3/2/2009 |
|
3W | $18.82 | +30.04% | +502.23% | +472.19 | 0 Comment | |
| foolrrrrrrrrrr | 33.18 | 11/13/2008 |
|
1Y | $37.61 | -34.91% | +420.99% | +455.89 | 0 Comment | |
| Dennyf10 | 68.24 |
|
|
1Y | $35.72 | -31.48% | +380.95% | +412.42 | 0 Comment | |
| hackerbobZ | < 20 | 3/23/2009 |
|
5Y | $17.65 | +38.68% | +450.69% | +412.01 | 0 Comment | |
| deemonfather42 | < 20 | 7/6/2009 |
|
3W | $22.42 | +9.18% | +382.16% | +372.98 | 0 Comment | |
| kozmo66 | < 20 | 9/22/2008 |
|
3M | $38.69 | -36.73% | +253.38% | +290.11 | 0 Comment | |
| MARTIJN76 | 94.43 | 10/19/2006 |
|
3M | $35.60 | -31.23% | +234.07% | +265.30 | 0 Comment | |
| TheDecider | 34.00 | 1/27/2011 |
|
5Y | $34.90 | -29.86% | +230.48% | +260.34 | 0 Comment | |
| SmallCapSurfer2 | 54.27 | 10/13/2016 |
|
3M | $5.32 | +360.15% | +102.27% | +257.88 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
